MichBIO Spring 2026 BioMatters: Turning a Scientific Challenge into a Promising New Cancer Drug Jul 16, 2026, 09:00 ET SciTech and ST-001 nanoFenretinide™ were profiled in the MichBIO Spring 2026 quarterly magazine. Read more below. Link MEDIA CONTACT David Schaffer +1-727-278-8188DRS@SciTechDevelopment.com
Clinical Data on ST-001 nanoFenretinide™ to be presented at USCLC Annual Workshop 2026 NEWS PROVIDED BY SciTech Development, Inc. Mar 25, 2026, 09:00 ET Results Highlight Early Clinical Benefit, High Systemic Exposure, and Manageable Toxicity in Cutaneous T-Cell Lymphoma Patients DETROIT, March 25, 2026 /PRNewswire/ — SciTech Development Inc., a clinical-stage oncology company advancing…
SciTech Development Strengthens Leadership Team with Appointment of Dr. Peter Littrup as Medical Director and Joseph Kraus to Advisory Board NEWS PROVIDED BY SciTech Development, Inc. Oct 21, 2025, 09:00 ET New appointments bolster clinical and financial leadership as SciTech advances its Series A financing and oncology trial expansion. DETROIT, Oct. 21, 2025 /PRNewswire/…
SciTech Development Announces the Closing of Oversubscribed $5.5 Million Funding Round to Continue Cancer Clinical Trials NEWS PROVIDED BY SciTech Development, Inc. Sep 24, 2025, 09:00 ET Investor confidence is fueled by remarkable interim clinical trial results for its drug, ST-001 nanoFenretinide™, showing 100% disease control at higher dose levels. DETROIT, Sept. 24, 2025…
SciTech Second Quarterly 2025 Newsletter NEWS PROVIDED BY SciTech Development 11 Jun, 2025, 09:00 ET DETROIT, Jun. 11, 2025 — Read the latest Second Quarterly 2025 newsletter here. This captures all the updates including strong early data in T-cell lymphoma, FDA approval on our second IND for small cell lung cancer trial, expanded manufacturing, $20M Series A launch,…
2025 American Society of Clinical Oncology (ASCO) Annual Meeting Poster Presentation: ST-001 nanoFenretinide™ Trial in Patients with T-cell Non-Hodgkin Lymphoma NEWS PROVIDED BY SciTech Development 05 Jun, 2025, 09:00 ET CHICAGO, Jun. 5, 2025 — SciTech Development presented a poster at the June 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, showcasing the…
SciTech Development Announces 2nd FDA Approval of a Phase 1 a/b IND For ST-001. New IND Targets the Treatment of Relapsed/Refractory Small Cell Lung Cancer Following Its Previous Approval in the Treatment of T-Cell NHL NEWS PROVIDED BY SciTech Development, Inc. Apr 08, 2025, 09:00 ET GROSSE POINTE FARMS, Mich., April 8, 2025 /PRNewswire/ –…
SciTech Development Advances to Next Stage of Clinical Trial for ST-001 nanoFenretinide™ NEWS PROVIDED BY SciTech Development 13 Jan, 2025, 09:00 ET **Encouraging Data from Accelerated Trial Supports Progress for T-cell Non-Hodgkin Lymphoma.** DETROIT, Jan. 13, 2025 /PRNewswire/ — SciTech Development, a clinical-stage pharmaceutical company specializing in oncology, is pleased to announce the initiation…
Scitech Development Welcomes Ken Massey Ph.D., as Strategic Operations Advisor NEWS PROVIDED BY SciTech Development 10 Dec, 2024, 09:00 ET DETROIT, Dec. 10, 2024 /PRNewswire/ — SciTech Development is thrilled to welcome Ken Massey, Ph.D., as Strategic Operations Advisor. With a wealth of experience in drug development, Dr. Massey has played a pivotal role in…
Scitech Development Announces Promising Preliminary Results in Phase 1a Trial for T-cell Non-Hodgkin Lymphoma NEWS PROVIDED BY SciTech Development 03 Dec, 2024, 10:00 ET **Multiple Early Partial Responses Alongside Encouraging Safety and Pharmacokinetic Data** DETROIT, Dec. 3, 2024 /PRNewswire/ — SciTech Development, a clinical-stage pharmaceutical company focused on advancements in cancer treatment, is excited…